Physician profile
Amanda Moukdad
NPI 1326605528
$3,784.68
in general payments reported to CMS, 2019-2025
33 companies · $51.46 in 2025
The $51.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $369 · 2023: $2,139 · 2024: $1,225 · 2025: $51.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $667.25 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $458.29 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.80 | 2023-2025 | Jardiance |
| Corcept Therapeutics | $314.99 | 2022-2023 | Korlym |
| Novo Nordisk INC | $272.53 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Intra-Sana Laboratories | $262.96 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $231.64 | 2022-2024 | Spravato, Xarelto |
| Inari Medical, INC. | $132.50 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.07 | 2023-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $95.33 | 2024 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $91.63 | 2022-2024 | Fasenra, Farxiga |
| Lilly USA, LLC | $85.49 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Tolmar, INC. | $77.08 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $71.85 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $67.22 | 2022-2024 | Eliquis, Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67.11 | 2023 | |
| Almatica Pharma LLC | $62.18 | 2023-2024 | Loreev Xr |
| Exact Sciences Corporation | $49.11 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $42.29 | 2023 | Quviviq |
| Aurinia Pharma U.S., INC. | $35.23 | 2022 | |
| Amgen INC. | $32.29 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $31.75 | 2023-2024 | Rexulti |
| Recordati_rare_diseases_inc. | $29.57 | 2023 | Isturisa, Signifor Lar |
| Edwards Lifesciences Corporation | $20.68 | 2024 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $18.33 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.49 | 2023 | |
| Horizon Therapeutics Plc | $16.54 | 2023 | Tepezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.35 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $15.97 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $14.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.81 | 2023 | Nuzyra |
| Astellas Pharma US INC | $13.74 | 2023 | Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Moukdad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.